According to a study published in the journal Lancet, a common diabetes drug can be used to treat certain adults with chronic kidney disease (CKD). Dapagliflozin belongs to a class of drugs known as SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors).

The SGLT2 protein in the kidneys is blocked by an SGLT2 inhibitor. By reducing pressure and inflammation in the kidneys, blocking this protein helps to prevent kidney damage. It also reduces blood pressure and body weight by preventing protein from leaking into the urine.

Dapagliflozin reduces the rate of kidney function decline in patients with chronic kidney disease, according to a clinical trial involving 4,304 patients with CKD (CKD). The attendees were split into two groups: Standard care was supplemented with dapagliflozin 10 mg or placebo once daily. Although dapagliflozin also slowed the decline of kidney function in those without diabetes, the effect of dapagliflozin was greater in those with diabetes. "The key finding is that dapagliflozin is an effective treatment for slowing progressive kidney function loss in patients with CKD who also have type 2 diabetes," said Hiddo Lambers Heerspink, the study's lead author from the University Medical Center Groningen.

Scientists discover commonly found parasite that could treat certain types of cancer

Study shows COVID-19 infection is less severe thanks to a new antibody

Zika Virus Patient goes through Treatment In UP's Kanpur, 22 Samples Test Negative